ACTION观察性研究中类风湿关节炎患者12个月静脉阿巴西普保留率的真实世界预测因素
ACTION是一项国际观察性研究,纳入2364例中重度类风湿关节炎患者(674例生物制剂初治、1676例生物制剂失败),分析12个月静脉阿巴西普保留率及预测因素。初治组12个月粗保留率78.1%(95%CI 74.7%–81.2%)显著高于失败组69.9%(95%CI 67.6%–72.1%),P<0.001;类风湿因子/抗CCP双阳性与更高保留率相关。
要点
- 生物制剂初治组12个月阿巴西普保留率78.1%显著高于失败组69.9%(P<0.001)。
- 类风湿因子/抗CCP双阳性在两组均预测更高保留率,在侵蚀性疾病患者中仍相关。
- BMI不影响阿巴西普保留率,与RF/抗CCP血清状态无关;无新安全信号。
核心结论
- 真实临床实践中静脉阿巴西普保留率高,尤其在生物制剂初治患者中,包括具有不良RA预后因素者。
- BMI不影响保留率,无论RF/抗CCP血清状态如何。
研究设计与样本
- ACTION为国际观察性研究,纳入中重度类风湿关节炎并启动静脉阿巴西普治疗的患者。
- 本次为2年研究中的12个月中期分析,评估粗保留率、保留预测因素及EULAR反应;共2350/2364例可评估(生物制剂初治674例,生物制剂失败1676例)。
主要发现
- 12个月粗保留率(95%CI)生物制剂初治组78.1%(74.7%–81.2%)vs 生物制剂失败组69.9%(67.6%–72.1%),初治组显著更高(P<0.001)。
- RF/抗CCP双阳性在两组均预测更高保留率,在侵蚀性疾病患者中仍与更高保留率相关。
- BMI在两组均不影响阿巴西普保留率,与RF/抗CCP血清状态无关。
- 12个月EULAR良好/中度反应率生物制剂初治组83.8% vs 生物制剂失败组73.3%(数值上更高)。
- 无新安全信号。
关键数值与推荐
- 12个月粗保留率(95%CI):生物制剂初治组78.1%(74.7%–81.2%)vs 生物制剂失败组69.9%(67.6%–72.1%),P<0.001。
- 12个月EULAR良好/中度反应率:生物制剂初治组83.8% vs 生物制剂失败组73.3%(数值比较)。
- RF/抗CCP双阳性与两组更高保留率相关,在侵蚀性疾病患者中仍相关;BMI不影响保留率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: An understanding of real-world predictors of abatacept retention is limited. We analysed retention rates and predictors of abatacept retention in biologic-naïve and biologic-failure patients in a 12-month interim analysis of the 2-yearAbataCepTIn rOutiNe clinical practice (ACTION) study. METHODS: ACTION was an international, observational study of patients with moderate-to-severe rheumatoid arthritis (RA) who initiated intravenous abatacept. In this 12-month interim analysis, crude abatacept retention rates, predictors of retention and European League Against Rheumatism (EULAR) response were evaluated in both biologic-naïve and biologic-failure patients. Retention by rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) status was also assessed, in patients with or without baseline radiographic erosions, and by body mass index (BMI). RESULTS: Overall, 2350/2364 enrolled patients were evaluable (674 biologic naїve; 1676 biologic failure). Baseline characteristics were largely similar in biologic-naïve and biologic-failure groups. Crude retention rates (95% CI) at 12 months were significantly higher in biologic-naїve (78.1%(74.7% to 81.2%)) versus biologic-failure patients (69.9%(67.6% to 72.1%); P<0.001). RF/anti-CCP double positivity predicted higher retention in both patient groups, and remained associated with higher retention in patients with erosive disease. BMI did not impact abatacept retention in either patient group, irrespective of RF/anti-CCP serostatus. Good/moderate EULAR response rate at 12 months was numerically higher in biologic-naїve (83.8%) versus biologic-failure (73.3%) patients. There were no new safety signals. CONCLUSION: High levels of intravenous abatacept retention in clinical practice were confirmed, particularly in biologic-naïve patients, including in those with poor RA prognostic factors. Retention was unaffected by BMI, regardless of RF/anti-CCP serostatus. TRIAL REGISTRATION NUMBER: NCT02109666; retrospectively registered 8 April 2014.
引用
- Alten R, Mariette X, Lorenz HM, et al. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open. 2017. PMID: 29435360. doi:10.1136/rmdopen-2017-000538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。